



Dr. Dhananjay Bakhle

Executive Vice President – Medical Research

Dr. Dhananjay Bakhle is responsible for the Medical Research group at Lupin. This group comprises of global clinical development of biosimilars and new chemical entities, global pharmacovigilance activities (DSRM) and Lupin Bio-research Center (LBC). With over 30 years of experience, he has been a Medical & Regulatory Director for several companies such as Sanofi, Aventis, Novartis, Fulford & also Lupin (between 1995-2000) in the past. Dr. Bakhle created a Phase I unit for Glaxo in 1988 which he headed for 4 years, created the global development center for Novartis in 2000 and a global medical writing group for Aventis in 2004. He headed Reliance Clinical Research Services (RCRS) for two years before rejoining Lupin in 2009.

He was instrumental in creating a super-specialty course of DM (Clinical Pharmacology) as a member, Board of Studies at University of Bombay. He was a member of several regulatory committees that framed guidelines for GCP, Bioequivalence, IPR, Phase I and Ethical Marketing Code during the period of 1990-2010. He has held the position of Vice-Chairman of the medical committee of OPPI and was an active member of technical committee of IDMA for several years. He was a member of WHO's research advisory committee on TB and was an active member of Global Alliance against TB in the past. He has been profiled in the book "Thought Leaders" published by Tata Mcgraw Hill, amongst 22 corporate leaders from different sectors of industry in India.

Dr. Bakhle is an MD from Mumbai University.